Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients.

A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 give no remarkable advantages to the pancytokeratin cocktail of antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in detecting disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. | LitMetric